Roche Says Product Launches, Investments Go Unabated In India Irrespective Of Patent Controversies; Speaks Out On Patient Access Programs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Battling controversial patent litigations has neither deterred Swiss drug maker Roche from introducing new drugs in the Indian market nor has the company held back investments for growth in the country in fear of debatable intellectual property issues. That direct message was sent across by Roche India's Managing Director Girish Telang as he stressed hard to prove that his company had not exorbitantly priced a range of life saving drugs
You may also be interested in...
Setback For Roche As Delhi Court Dismisses Patent Claims On Tarceva; Cipla Allowed To Market Copies
MUMBAI - A sensational fight that lasted more than a year between Roche and India's Cipla over the patentability of anti-cancer drug Tarceva (erlotinib) ended in a defeat for the Swiss drug maker as the Delhi High Court in a landmark decision dismissed its patent claims
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).